Antiphospholipid Syndrome Collaborative Registry (APSCORE) - Full Text View

Purpose

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals.

The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.

Condition

Antiphospholipid Syndrome

MedlinePlus related topics:

Autoimmune Diseases

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective

Official Title:	Antiphospholipid Syndrome Collaborative Registry (APSCORE)

Further study details as provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS):

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Serum, plasma, genomic DNA

Estimated Enrollment:	2000
Study Start Date:	April 2000

Detailed Description:

Registry participants will have a blood sample drawn and will be interviewed about their medical histories. Participants will be asked to return for a follow-up visit after two years. Clinical, demographic, and laboratory data will be collected. Registry resources will be made available to researchers and medical practitioners to support a broad range of research on the causes, diagnosis, mechanisms, and treatment of APS.

The University of North Carolina at Chapel Hill is the coordinating center and an enrollment site for the registry. There are seven other enrollment sites: Ball Memorial Hospital, Muncie, IN; Duke University, Durham, NC; Hospital for Special Surgery, New York, NY; Johns Hopkins University, Baltimore, MD; Morehouse School of Medicine, Atlanta, GA; University of Texas Health Science Center, San Antonio, TX; and University of Utah Health Science Center, Salt Lake City, UT.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Specialty and subspecialty clinics

Criteria

Inclusion Criteria:

Antiphospholipid antibodies with or without associated clinical manifestations

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00076713

Locations


United States, Georgia
	Morehouse School of Medicine
	Atlanta, Georgia, United States, 30310

United States, Maryland
	Johns Hopkins University
	Baltimore, Maryland, United States, 21205

United States, New York
	Hospital for Special Surgery, Weill-Cornell University Medical Center
	New York, New York, United States, 10021

United States, North Carolina
	University of North Carolina at Chapel Hill
	Chapel Hill, North Carolina, United States, 27599
	Duke University Medical Center
	Durham, North Carolina, United States, 27710

United States, Texas
	University of Texas Health Science Center
	San Antonio, Texas, United States, 78229

United States, Utah
	University of Utah Health Science Center
	Salt Lake City, Utah, United States, 84132

Sponsors and Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Center on Minority Health and Health Disparities (NCMHD)

More Information

Click here for the APSCORE Web site. This link exits the ClinicalTrials.gov site

Publications:

Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 2003 Nov;48(11):3004-8. Review. No abstract available.

Responsible Party:	University of North Carolina at Chapel Hill ( Robert A. S. Roubey, MD )
Study ID Numbers:	NIAMS-099
First Received:	February 2, 2004
Last Updated:	March 19, 2008
ClinicalTrials.gov Identifier:	NCT00076713
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS):

Antiphospholipid

Study placed in the following topic categories:

Autoimmune Diseases

Antiphospholipid syndrome

Antiphospholipid Syndrome

Additional relevant MeSH terms:

Pathologic Processes

Disease

Immune System Diseases

Syndrome

ClinicalTrials.gov processed this record on August 21, 2008

Sponsors and Collaborators:	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Center on Minority Health and Health Disparities (NCMHD)
Information provided by:	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier:	NCT00076713